Navigation Links
Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
Date:5/5/2008

ANN ARBOR, Mich., May 5 /PRNewswire/ -- Assay Designs, Inc., a leading provider of immunoassay kits, antibodies, and reagents to the life sciences and translational research markets, announced a collaboration on a joint antibody research project with the Medical University of South Carolina and Dr. Jennifer Isaacs' laboratory. Under the terms of this agreement, Assay Designs will provide anti-Heat shock protein 90 (Hsp90) antibody for both cell-based and animal-based work.

This collaboration agreement will allow Dr. Isaacs to move forward with research investigating the role of Hsp90 in the progression of many cancers. "I am excited about the prospect of utilizing this antibody to target the Hsp90 chaperone and to potentially curtail the metastatic properties of some cancers. Moreover, we now have a new tool to explore the role of cell surface localized Hsp90 protein in cancer progression. Since this antibody is well-tolerated in animals, this approach paves the way for a promising therapeutic strategy, " stated Dr. Isaacs.

"As the leader in heat shock proteins (HSPs) and chaperones, collaborations such as this provide valuable insight for our new product development efforts," stated Dan Calvo, Assay Designs' President and CEO. "Supporting the validation of new and novel test protocols enhances the value and flexibility of our broad HSP product portfolio."

About Assay Designs, Inc.

Based in Ann Arbor, MI, Assay Designs develops, manufactures and markets immunoassay (ELISA) kits, antibodies, and proteins that are used for life sciences research. The company markets these products under the "Assay Designs" and "Stressgen" brand names. Researchers use Assay Designs products to detect and quantify molecules that are important biomarkers of inflammation, heat shock, cell signaling, and oxidative stress.

About Isaacs Lab.

A long-term research goal of the Isaacs Lab is to better understand the role of Hsp90 in tumor progression to ultimately optimize the use and potency of Hsp90 inhibitors in the clinic. In particular, the lab investigates how Hsp90 contributes to angiogenic processes and cell migration, representing two fundamental and universal aspects of cancer progression. Specifically, the tumor-promoting roles of Hsp90 are being assessed in various invasive cancers, such as prostate, renal cell carcinoma (RCC), and the deadly disease glioblastoma (GBM). Clinically relevant orthotopic models of RCC and GBM are being used and newer forms of Hsp90 antagonists are being evaluated. In collaboration with other groups, there is also interest in identifying combination treatments most effective against these cancers.


'/>"/>
SOURCE Assay Designs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
2. Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
3. Genetic Engineering & Biotechnology News Reports on Growing Use of Cell-Based Assays
4. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
5. Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
6. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
7. Data Presented on Monogram HIV Tropism Tests at Retrovirus Conference sets New Standards of Assay Sensitivity
8. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
9. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
10. Study Reaffirms Superiority of Trofile(TM) Assay
11. EpiCept to Present Pre-clinical Advances of Myc Oncogene Directed Drug Discovery at Assays and Cellular Targets Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... ... May 22, 2016 , ... Doctors in Rome say micronutrients ... asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on the new ... of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than 150 studies ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... - I dati saranno presentati nel ... ° Congresso della Società Americana di Oncologia ... conclusioni dello studio indicano un tasso di risposta del 56% ... presenta una d urata della risposta (Duration Of Response, ... dei pazienti ha riscontrato un beneficio clinico.      ...
(Date:5/18/2016)... Fort Washington, PA (PRWEB) , ... May 18, ... ... and at least 1,200 hospitalizations are a direct result of asthma complications.* Costing ... health challenge across the country. , “For too many, the ...
Breaking Biology Technology:
(Date:3/31/2016)... RATON, Florida , March 31, 2016 ... LEGX ) ("LegacyXChange" or the "Company") ... for potential users of its soon to be launched ... video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide ... the use of DNA technology to an industry that ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
Breaking Biology News(10 mins):